Primary breast double-hit lymphoma management and outcomes: a real-world multicentre experience

Zhang, Tingting; Zhang, Yuanfeng; Fei, Hairong; Shi, Xue; Wang, Liang; Wang, Peijun; Yu, Jie; Shen, Yuyan; Feng, Sizhou

doi:10.1186/s12935-021-02198-y

Cancer Cell International

Table 4 Univariate and multivariate analysis for OS and PFS in the study cohort

From: Primary breast double-hit lymphoma management and outcomes: a real-world multicentre experience

Factors	Univariate analysis						Multivariate analysis
	OS			PFS			OS			PFS
	HR	95% CI	P-value	HR	95% CI	P-value	HR	95% CI	P-value	HR	95% CI	P-value
Age
≤ 50 years	1.0	0.5–2.1	0.965	0.9	0.4–1.9	0.845
50–60 years
Laterality
Left	0.3	0.1–0.7	0.005	0.3	0.1–0.6	0.003	3.580	0.475-26.969	0.216	2.215	0.326–15.045	0.416
Right	0.2	0.1–0.6	0.003	0.2	0.1–0.6	0.004	0.848	0.170–4.230	0.840	0.673	0.142–3.198	0.618
Bilateral
Tumor size
≥ 5 cm	2.3	1.1–4.9	0.030	2.3	1.1–4.8	0.022	4.771	1.624–14.020	0.004	4.517	1.643–12.416	0.003
< 5 cm
Cell of origin
GCB	1.1	0.4- 3.0	0.776	1.2	0.5–3.1	0.712
Non-GCB
Results of FISH
MYC-BCL2	0.5	0.2–1.2	0.114	0.6	0.3–1.3	0.199
MYC-BCL6
BCL2 of IHC
BCL2 +	1.3	0.2–9.4	0.809	1.4	0.2–10.3	0.743
BCL6 of IHC
BCL2 = 6 +	0.9	0.2–3.7	0.862	1.0	0.2–4.2	0.991
CD5 of IHC
CD5 +	1.8	0.8–3.7	0.144	1.6	0.7–3.2	0.240
CD10 of IHC
CD10 +	1.1	0.5–2.4	0.759	1.1	0.5–2.3	0.785
P53 of IHC
P53 +	1.4	0.6–3.3	0.452	1.6	0.7–3.7	0.295
Ann Arbor staging
IE	0.1	0-0.4	0.001	0.1	0-0.5	0.001	1.4	0.1–21.7	0.801	5.3	0. 4-68.7	0.203
IIE	0.3	0.2–0.8	0.010	0.4	0.2–0.8	0.009	0.9	0.1–8.2	0.903	1.9	0.2–16.3	0.558
IV
B symptom
Absent	0.4	0.2-1.0	0.057	0.5	0.2-1.0	0.062	0.5	0.2–1.4	0.180	0.5	0.2–1.4	0.187
Present
LDH level
Normal	0.7	0.3–1.5	0.405	0.9	0.4–1.8	0.693
Elevated
Chromosomal abnormality
Present	0.9	0.4–2.2	0.869	0.9	0.4–2.1	0.811
Absent
Risk stratification
L and L-I	0.4	0.2–0.9	0.022	0.4	0.2–0.9	0.020	0.2	0–1.0	0.050	0.2	0–0.7	0.012
H and H-I
Breast irradiation
Yes	0.4	0.2–0.8	0.008	0.4	0.2–0.8	0.008	0.3	0.1-1.0	0.042	0.3	0.1–0.8	0.021
No
Chemical regimen
R-DAEPOCH	0.4	0.2–0.9	0.036	0.4	0.2-1.0	0.047	0.1	0-0.5	0.001	0.1	0-0.4	0.001
R-DAEPOCH/MA	0.3	0.1–0.8	0.013	0.3	0.1–0.9	0.029	0.2	0.1–0.6	0.007	0.3	0.1–0.8	0.018
R-HyperCVAD
ASCT
Yes	0.2	0.1–0.6	0.001	0.2	0.1–0.5	< 0.001	0.1	0–0.4	0.002	0.1	0-0.3	< 0.001

OS overall survival, PFS progression-free survival, HR hazard ratio, 95% CI 95% confidence interval, GCB germinal centre B-cel, LDH lactate dehydrogenase, L low-risk, L-I low-intermediate risk, H high-risk, H-I high-intermediate risk, R-HyperCVAD rituximab, hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, alternating with cytarabine plus methotrexate, DA-EPOCH-R rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, DA-EPOCH-R/MA rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, alternating with high-dose methotrexate and cytarabine, ASCT autologous stem cell transplantation

Back to article page

ISSN: 1475-2867

Contact us

General enquiries: journalsubmissions@springernature.com